Skip Navigation LinksHome > November 2012 - Volume 39 - Issue 11 > Prevalence and Correlates of Genital Warts in Kenyan Female...
Sexually Transmitted Diseases:
doi: 10.1097/OLQ.0b013e318275ec7f
Original Study

Prevalence and Correlates of Genital Warts in Kenyan Female Sex Workers

Kavanaugh, Barbara E. MPH*; Odem-Davis, Katherine PhD; Jaoko, Walter MBChB, PhD; Estambale, Benson MBChB, PhD; Kiarie, James N. MBChB, MMed, MPH; Masese, Linnet N. MBChB, MPH*‡; Deya, Ruth MBChB*; Manhart, Lisa E. PhD*; Graham, Susan M. MD, MPH, PhD; McClelland, Raymond Scott MD, MPH*‡

Free Access
Article Outline
Collapse Box

Author Information

From the *University of Washington, Seattle, WA; †Fred Hutchinson Cancer Research Center, Seattle, WA; ‡University of Nairobi, Nairobi, Kenya; and §Kenya Medical Research Institute, Kilifi, Kenya

We wish to acknowledge the study participants, who contributed their time and effort to make this study a success. We also wish to recognize the contributions made by our clinical, laboratory, and administrative staff. We thank the Mombasa Municipal Council for providing clinical space, and Coast Provincial General Hospital for providing laboratory space.

Supported by the National Institutes of Health (NIH; grant P01-HD64915). Infrastructure support for the Mombasa Field Site was received from the University of Washington Center for AIDS Research, an NIH-funded program (P30-AI027757). The Fogarty International Center provided training support for L.N.M. and R.D. (grant 5D43-TW000007).

The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. All authors claim no conflict of interest.

Correspondence: R. Scott McClelland, MD, MPH, University of Washington, Box 359909, 325 Ninth Ave, Seattle, WA 98104. E-mail: mcclell@u.washington.edu.

Received for publication March 27, 2012, and accepted June 26, 2012.

Collapse Box

Abstract

Background: Our goal in the present study was to investigate the prevalence and correlates of genital warts in a population of female sex workers in Mombasa, Kenya. Because of the high prevalence of human immunodeficiency virus type 1 (HIV-1) in this population, we were particularly interested in the association between HIV-1 infection and genital warts.

Methods: We conducted a cross-sectional study of the prevalence and correlates of genital warts among high-risk women in Mombasa, Kenya. Between 2001 and 2007, 1182 women were enrolled, of whom 613 (51.4%) were HIV-1 seropositive. Chi square tests and logistic regression were used to examine the associations between genital warts and potential correlates.

Results: Genital warts were identified on clinical examination in 27 (2.3%) women. Women who were HIV-1 seropositive were nearly 8 times as likely to have genital warts compared with HIV-1–seronegative women (odds ratio, 7.69; 95% confidence interval, 2.30–25.6).

Conclusion: Understanding the prevalence and correlates of genital warts will help to determine whether coverage for the wart-inducing subtypes 6 and 11 in a human papillomavirus vaccine is an important consideration in resource-limited countries.

Sub-Saharan Africa has a high prevalence of both human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV).1,2 In this context, it is important to note that HIV-1 infection may facilitate transmission and acquisition of HPV,3,4 as well as the development of clinically evident genital warts in those coinfected with both viruses.5,6 Of 140 identified subtypes of HPV, subtypes 16 and 18 cause approximately 70% of cervical cancer, whereas subtypes 6 and 11 are responsible for approximately 90% of genital warts.7 Few studies have characterized the prevalence and correlates of genital warts in sub-Saharan Africa, but prevalence is believed to be high in all parts of the world.8

Currently, 2 vaccines are available for HPV prevention. One is bivalent and protects against subtypes 16 and 18 (Cervarix, GlaxoSmithKline). The other is quadrivalent and protects against infection with subtypes 6, 11, 16, and 18 (Gardasil, Merck). Both are more than 95% effective in preventing cervical cancer, and the quadrivalent vaccine is equally effective in preventing genital warts.9,10

Both vaccines have been licensed in parts of sub-Saharan Africa, and pilot projects assessing HPV vaccine acceptability and feasibility have been conducted in the region.11 At present, only Rwanda has a national policy for HPV vaccination,12 but other resource-limited countries may find it easier to finance HPV vaccination in the near future. In November 2011, Merck offered a price of $5 per dose for their quadrivalent vaccine to the GAVI Alliance. Discussions are underway with GlaxoSmithKline about reduced pricing options for the bivalent vaccine.13 With the availability of HPV vaccines that differ mainly in their ability to prevent genital warts, knowledge of the prevalence and correlates of genital warts in sub-Saharan Africa will be useful in program planning. A substantial prevalence of genital warts would suggest that populations in these areas might benefit from vaccination including coverage for the genital wart–associated HPV subtypes.

Our objective was to investigate the prevalence and correlates of genital warts in a population of female sex workers in Mombasa, Kenya. Because of the high prevalence of HIV-1 in this population, we were particularly interested in the association between HIV-1 infection and genital warts.

Back to Top | Article Outline

MATERIALS AND METHODS

This cross-sectional analysis used data from enrollment visits of an open cohort study at a municipal communicable disease clinic in Mombasa, Kenya. Cohort procedures have been published in detail.14 Briefly, subjects were interviewed for demographic, medical, and sexual histories. Women who were HIV-1 seropositive and HIV-1 seronegative were enrolled, regardless of the presence or absence of reported symptoms. A physical examination including a speculum-assisted pelvic examination was performed by an experienced research clinician and included documenting the presence of genital warts specifically on the vulva, vagina, or cervix. Before collecting data independently, research clinicians were mentored in the diagnosis of genital pathology by trained sexually transmitted disease clinicians, and a pictorial atlas of sexually transmitted diseases was posted in the examination room to aid diagnosis. Patients with lesions that were clinically concerning for cancer or were too large to treat with cryotherapy or podophyllin were referred for surgical consultation. Laboratory screening for HIV-1 and other genital tract infections was performed. This study was approved by the human subjects research committees of Kenyatta National Hospital and the University of Washington. Written informed consent was obtained from all participants.

There were 1252 participants enrolled between March 2001 and December 2007. We excluded 70 (5.6%) women with missing or inconclusive HIV-1 status or genital wart data. Thus, our analyses included 1182 women. Human immunodeficiency virus type 1 serostatus was determined by enzyme-linked immunosorbent assay (Detect HIV1/2 [BioChem Immunosystems, Montreal, Canada] or PT-HIV 1,2-96 [Pishtaz Teb Diagnostics, Tehran, Iran]). Positive samples were confirmed using a second enzyme-linked immunosorbent assay (Recombigen [Cambridge Biotech, Worcester, MA] or Vironostika HIV-1 Uniform IIAG/AB [bioMerieux, Marcy l’Etoile, France]). A vaginal saline wet mount was examined for the presence of yeast on microscopy. Bacterial vaginosis was diagnosed using the criteria of Nugent et al.15

Analyses were performed using SPSS (version 17.0; IBM) and R (version 2.13, ISBN 3-900051-07-0). The 95% confidence interval (CI) for prevalence of genital warts was estimated by bootstrap sampling. Associations between the presence of genital warts and enrollment characteristics were evaluated using univariate Mantel-Haenszel odds ratio (OR) estimates with corresponding χ2 tests. Variables associated with genital warts in univariate analysis (P < 0.1) were included in a multivariate logistic regression model. In the multivariate model, age was dichotomized as less than or equal to 30 or greater than 30 years based on the median age of the subjects in the cohort.

The association between a CD4 count less than 200 and the presence of genital warts for the subset of HIV-1–positive women was also assessed using Mantel-Haenszel OR estimates, a χ2 test, and multivariate logistic regression. Potential confounding factors associated with genital warts among HIV-1–positive women in univariate analysis (P < 0.1) were included in the multivariate model.

Back to Top | Article Outline

RESULTS

Of the 1182 women enrolled between March 2001 and December 2007, 613 (51.4%) were HIV-1 seropositive. Genital warts were identified in 27 (2.3%; 95% CI, 1.4%–3.1%) women. Of these, 20 (74%) had vulvar lesions, 13 (48%) had vaginal lesions, and 3 (11%) had cervical lesions. These percentages add up to more than 100% because some women had genital warts in multiple locations. The anatomical locations of genital warts did not differ significantly by HIV status (data not shown). Baseline characteristics of the women are presented in Table 1.

Table 1
Table 1
Image Tools

Genital warts were observed in 24 (3.9%) HIV-1–seropositive women versus 3 (0.5%) HIV-1–seronegative women (OR, 7.69; 95% CI, 2.30–25.6) (Table 2). There was a higher prevalence of genital warts in women with vaginal yeast compared with those without (OR, 2.92; 95% CI, 0.95–5.51), although this association was not statistically significant. Results were similar in a multivariate model that included both HIV-1-serostatus and the presence of vaginal yeast.

Table 2
Table 2
Image Tools

Among the 518 HIV-1–seropositive women with available CD4 counts, the risk of genital warts was significantly greater among the 104 (20%) women with CD4 less than 200 compared with those with CD4 of 200 or greater (OR, 2.92; 95% CI, 1.08–7.85). The association between CD4 count and the presence of genital warts was similar in an analysis that adjusted for age (OR, 3.13; 95% CI, 1.14–8.57).

Back to Top | Article Outline

DISCUSSION

The prevalence of genital warts in this population of high-risk women was 2.3%. Women who were HIV-1 seropositive were nearly 8 times as likely to have genital warts compared with those who were HIV-1 seronegative. Among those who were HIV-1 seropositive, genital warts were more common when CD4 counts were less than 200 cells/μL.

Our results showing a modest prevalence of genital warts among female sex workers in Kenya parallel those across a range of settings in sub-Saharan Africa.3,4,16–20 In addition, our findings are similar to those of studies showing that genital warts are more common with HIV and with progressive immunosuppression.16–20 This finding may be a result of HIV-1 infection prolonging the duration and increasing the recurrence rate of HPV infection5,21 and suggests that the quadrivalent vaccine could be particularly important as a public health consideration in populations with high HIV-1 infection prevalence. Specifically, where the older girls and young women who would be vaccinated have a high lifetime risk of both HIV and HPV infections, vaccination before coitarche using a vaccine that prevents infection with the genital wart–associated HPV subtypes could substantially reduce the population-level prevalence of genital warts.

We found a modest association between genital warts and the presence of yeast, which was of borderline statistical significance after adjusting for HIV-1 serostatus. These findings could be explained on the basis of genital warts providing an environment that facilitates local colonization with yeast. In light of the multiple statistical comparisons presented, it should also be noted that this association could have occurred by chance.

One of the strengths of this study was a large sample size. In addition, our ability to recruit from a population of high-risk women who were invited to the clinic for routine HIV-1 and sexually transmitted infection screening may have reduced bias. Female sex workers in this community attended the clinic even when they were asymptomatic. This study design may have reduced the risk for bias toward an overestimate of the population prevalence of genital warts compared with studies in cohorts presenting primarily because of symptoms, such as sexually transmitted infection clinic attendees.

These findings should be interpreted in the context of a number of limitations. The point prevalence of genital warts was modest, so we had limited power to explore correlates. Data on participant complaints regarding genital lesions, the number and morphology of genital warts and anal or perineal warts, or the presence of giant warts (Buschke-Lowenstein tumors) were not collected. Although patients with clinically concerning lesions and those too large for treatment with cryotherapy or podophyllin were referred for surgical consultation, we do not have data about their surgical pathology and did not systematically collect information about postoperative outcomes. No HPV testing was performed. The population in this study included only high-risk women based on self-reported transactional sex. Their HIV-1 prevalence is much higher than that of Kenya generally,22 and they could also have had a higher risk of HPV. On the other hand, some women with large or numerous genital warts might have been unable to work as sex workers, and so they would not have presented to our clinic. Finally, cross-sectional design limits any determination of whether HIV-1 infection or HPV was the original infection or whether one increased susceptibility to the other.

These results are timely, given current discussions around selection of HPV vaccines for use in different settings. The cost of the different vaccines will also be an important factor. If there is no difference in cost, then the quadrivalent vaccine would seem to have a clear advantage. However, if the cost of the bivalent vaccine is lower, then the medical and psychosocial costs of genital warts must be weighed against the added cost of the quadrivalent vaccine. Cost-effectiveness studies modeling the expected quality-adjusted life-years saved by the quadrivalent versus bivalent vaccine could be beneficial. Whether protection against genital warts influences acceptability and uptake of vaccination in different populations may also be important to consider.

In conclusion, our results demonstrate a modest point prevalence of genital warts in this population of high-risk women, suggesting that their lifetime risk of genital warts may be substantial, consistent with other studies of lifetime prevalence of genital warts in various parts of the world.23,24 Understanding the prevalence and correlates of genital warts in different populations will be useful for determining the importance and cost-effectiveness of using a quadrivalent versus bivalent HPV vaccine.

Back to Top | Article Outline

REFERENCES

1. HPV human papillomavirus and related cancers summary report update [World Health Organization and Catalan Institute of Oncology (WHO/ICO) Information Centre on HPV and cervical cancer Web site]. November 15, 2010. Available at: http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/XWX.pdf?CFID=5154994&CFTOKEN=53348681. Accessed on July 14, 2011.

2. HIV in Africa [USAID Web site]. Available at: http://www.usaid.gov/our_work/global_health/aids/Countries/africa/hiv_summary_africa.pdf. Accessed July 14, 2011.

3. Banura C, Franceschi S, van Doorn L-J, et al.. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008; 197: 555–562.

4. Silverberg MJ, Ahdieh L, Munoz A, et al.. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection on genital warts. Sex Transm Dis 2002; 29: 427–435.

5. Duerr A, Kieke B, Warren D, et al.. Human papilloma-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2000; 184: 584–590.

6. Clifford GM, Gallus S, Herrero R, et al.. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 2005; 366: 991–998.

7. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3–8.

8. Weekly Epidemiological Record of April 10, 2009 No. 15, Vo 84, 117–132 [World Health Organization Web site]. Available at: http://www.who.int/wer/2009/wer8415.pdf. Accessed July 14, 2011.

9. FDA approves expanded uses for Gardasil to include preventing certain vulvar and vaginal cancers [Food and Drug Administration News Releases Web site]. September 12, 2008. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116945.htm. Accessed July 14, 2011.

10. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions—The FUTURE II Study Group. N Engl J Med 2007; 356: 1915–1927.

11. Ladner J, Besson M-H, Hampshire R, et al.. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012; 12: 370 doi:10.1186/1471-2458-12-370.

12. Editorial, The Lancet. Financing HPV vaccination in developing countries. Lancet 2011; 377: 1544.

13. Nguyen A, Datta SD, Schwalbe N, et al and the GAVI Alliance. Working towards affordable pricing for HPV vaccines for developing countries: The role of GAVI. GTF.CCC Working Paper and Background Series, No. 3, Harvard Global Equity Initiative, 2011.

14. Martin HL, Nyange PM, Richardson BA, et al.. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178: 1053–1059.

15. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297–301.

16. Kreiss J, Kiviat NB, Plummer FA, et al.. Human immunodeficiency virus, human papillomavirus, and cervical intraepithelial neoplasia in Nairobi prostitutes. Sex Transm Dis 1992; 19: 54–59.

17. Low AJ, Clayton T, Konate I, et al.. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: A longitudinal study. BMC Infect Dis 2011; 11: 20.

18. Fonck K, Kidula N, Kirui P, et al.. Pattern of sexually transmited diseases and risk factors among women attending an STD clinic in Nairobi, Kenya. Sex Transm Dis 2000; 27: 417–423.

19. Low A, Didelot-Rousseau M-N, Nagot N, et al.. Cervical infection with human papillomavirus (HPV) 6 or 11 in high-risk women in Burkina Faso. Sex Transm Infect 2010; 86: 342–344.

20. Yamada R, Sasagawa T, Kirumbi LW, et al.. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol 2008; 80: 847–855.

21. Gingelmaier A, Grubert T, Kaestner R, et al.. High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1–infected women. Anticancer Res 2007; 27: 1795.

22. Factsheet for Kenya, HIV and AIDS Estimates [United Nations AIDS (UNAIDS) Web site]. 2009. Available at: http://www.unaids.org/en/regionscountries/countries/kenya/. Accessed July 30, 2011.

23. Dinh T-H, Sternberg M, Dunne E, et al.. Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999–2004. Sex Transm Dis 2008; 35: 357–360.

24. Kjaer SK, Tran TN, Sparen P, et al.. Genital wart burden in Nordic countries. J Infect Dis 2007; 196: 1447–1454.

© Copyright 2012 American Sexually Transmitted Diseases Association

Login